Products Categories
CAS No.: | 1405-41-0 |
---|---|
Name: | Gentamycin sulfate |
Molecular Structure: | |
Formula: | C21H43N5O7.H2SO4 |
Molecular Weight: | 575.67 |
Synonyms: | Gentalline;Pred-G S.O.P.;Gentocin (Veterinary);Gentocin (*sulfate*);Garamycin (TN);Gentacin;Geramycin;Gentocin;Prestwick_240;Septopal;Gentamicin,sulfate (salt);Gentamicin C complex sulfate;Gentamicins;Topagen (Veterinary);Gentamycin sulphat;Gentamycin Solution;Gentamicin sulphate;Alcomicin;Garasol (Veterinary); |
EINECS: | 215-778-9 |
Density: | == |
Melting Point: | 218-237 °C |
Boiling Point: | 797.6 °C at 760 mmHg |
Flash Point: | 436.2 °C |
Solubility: | water: 50 mg/mL |
Appearance: | White crystalline powder |
Hazard Symbols: | Xn |
Risk Codes: | 42/43 |
Safety: | 23-36/37-45-22-24/25 |
PSA: | 719.38000 |
LogP: | -1.26180 |
Formula of Gentamycin sulfate (CAS NO.1405-41-0): C21H43N5O7.H2SO4
Molecular Weight: 575.67
Flash Point: 436.2 °C
Enthalpy of Vaporization: 132.12 kJ/mol
Boiling Point: 797.6 °C at 760 mmHg
Melting point: 218-237 °C(lit.)
Structure of Gentamycin sulfate (CAS NO.1405-41-0):
IUPAC Name: 2-[4,6-Diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; sulfuricacid
Gentamycin sulfate (CAS NO.1405-41-0) can be used as biochemical reagent, for example in some medicine use, as the antibacterial medicine. And it can be the medicine for the treatment of sepsis, urinary tract infection, staphylococcus infection, endocarditis and other diseases.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
guinea pig | LD50 | subcutaneous | 600mg/kg (600mg/kg) | Chemotherapy Vol. 16, Pg. 105, 1968. | |
man | TDLo | intravenous | 21mg/kg/6D-I (21mg/kg) | Drug Intelligence and Clinical Pharmacy. Vol. 18, Pg. 596, 1984. | |
mouse | LD50 | intracrebral | 17300ug/kg (17.3mg/kg) | PERIPHERAL NERVE AND SENSATION: SENSORY CHANGE INVOLVING PERIPHERAL NERVE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE | Chemotherapy Vol. 15, Pg. 483, 1967. |
mouse | LD50 | intramuscular | 250mg/kg (250mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982. |
mouse | LD50 | intraperitoneal | 245mg/kg (245mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982. |
mouse | LD50 | intravenous | 47mg/kg (47mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Japanese Journal of Antibiotics. Vol. 39, Pg. 3164, 1986. |
mouse | LD50 | oral | > 11269mg/kg (11269mg/kg) | Drugs in Japan Vol. 6, Pg. 268, 1982. | |
mouse | LD50 | subcutaneous | 478mg/kg (478mg/kg) | Journal of Antibiotics. Vol. 23, Pg. 551, 1970. | |
rat | LD50 | intramuscular | 384mg/kg (384mg/kg) | Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. | |
rat | LD50 | intraperitoneal | 630mg/kg (630mg/kg) | BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Japanese Journal of Antibiotics. Vol. 26, Pg. 221, 1973. |
rat | LD50 | intravenous | 96mg/kg (96mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION | Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982. |
rat | LD50 | oral | > 5gm/kg (5000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Jitchuken Zenrinsho Kenkyuho. Central Institute for Experimental Animals, Research Reports. Vol. 8, Pg. 219, 1982. |
rat | LD50 | subcutaneous | 873mg(base)/k (873mg/kg) | Antibiotiki i Khimioterapiya. Antibiotics and Chemotherapy. Vol. 35(9), Pg. 26, 1990. | |
women | TDLo | intravenous | 45mg/kg/1W-I (45mg/kg) | Drug Intelligence and Clinical Pharmacy. Vol. 18, Pg. 596, 1984. |
GENTAMYCIN sulfate's human systemic effects: level changes for metals other than Na/K/Fe/Ca/P/Cl. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of SOx.
Hazard Symbols of Gentamycin sulfate (CAS NO.1405-41-0): Xn
Risk Codes: R42/43
R42/43:May cause sensitization by inhalation and skin contact.
Safety Description: S23;S36/37;S45
S23:Do not breathe vapour.
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
Gentamycin sulfate , its cas register number is 1405-41-0. It also can be called Garamycin ; and 2-[4,6-Diamino-3-[3-amino-6-(1-methylaminoethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexoxy]-5-methyl-4-methylamino-oxane-3,5-diol sulphate .